|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
KAI Pharmaceuticals, Inc. Announces Phase 1 Results of KAI-4169 for the Treatment of Secondary Hyperparathyroidism (SHPT)
7/20/2010 8:27:22 AM
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced the Company has completed enrollment in a Phase 1 study of KAI-4169, a novel pharmaceutical agent for the treatment of secondary hyperparathyroidism (SHPT), which is a frequent complication of end stage renal disease (ESRD). The Phase 1 study was a double-blind, randomized, placebo-controlled, rising single intravenous (IV) dose study to assess safety and tolerability of KAI-4169 in healthy male volunteers. Preliminary data from the study demonstrated KAI-4169 to be safe and well-tolerated and have confirmed the potency and activity of KAI-4169 by demonstrating dose-dependent reductions in parathyroid hormone and serum calcium levels. KAI plans to begin recruitment in a Phase 1b study in patients with ESRD and SHPT this quarter.
|
|
|
|
|
|
|
|
|
|
|